Compare DexCom, Inc. (DXCM) vs Uber Technologies Inc (UBER) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Uber Technologies Inc — how do they compare? DexCom, Inc. trades at $77.81 (market cap $28.06B), while Uber Technologies Inc trades at $73.61 (market cap $147.93B). The key difference: Uber Technologies Inc is far larger — about 5.3× DexCom, Inc.'s market cap, and DexCom, Inc. is trading nearer its 52-week high, Uber Technologies Inc nearer its low. Which is the better fit depends on your goals.
| DXCM | UBER | |
|---|---|---|
Market Cap | $28.06B | $147.93B |
Sector | Health | Industrials |
52-Week High | $89.53 | $100.10 |
52-Week Low | $54.84 | $68.61 |
Enterprise Value | $27.03B | $154.25B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $74.12, down 2.92% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with consistent revenue growth, expanding profit margins, and a track record of beating earnings estimates. Recent regulatory approvals for its G7 15-day CGM in Canada and pediatric clearance for its Stelo OTC system in the U.S. highlight ongoing product expansion.
The investment thesis centers on DexCom's leadership in the growing CGM market, supported by strong financial execution and analyst optimism. Key risks include competition from Abbott, the commercial unproven nature of expansion into non-insulin Type 2 diabetes patients, and potential disruption from GLP-1 drug adoption. The consensus price target of $84.33 suggests ~14% upside from current levels.
Uber Technologies (UBER) trades at $72.08, down 2.94% today, amid bearish technical signals despite strong fundamentals. The company reported robust 2025 results with $52.02B revenue and $10.05B net income, though 2026 projections show moderating growth. Recent news highlights strategic shifts toward autonomous vehicles with robotaxi pilots in Madrid and Munich, alongside cost-cutting measures including HR layoffs. Analyst consensus remains strongly bullish with an $108.92 price target, representing 51% upside potential from current levels.
Uber presents a compelling growth story with expanding profitability and market dominance, though near-term technical weakness and moderating 2026 earnings projections warrant caution. The autonomous vehicle expansion represents significant long-term opportunity, while competitive pressures and regulatory risks persist. With zero sell ratings and overwhelming analyst support, the stock appears fundamentally undervalued despite current bearish technical indicators.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Uber Technologies Inc
Uber Technologies is a technology provider that matches riders with drivers, hungry people with restaurants and food delivery service providers, and shippers with carriers. The firm's on-demand technology platform could eventually be used for additional products and services, such as autonomous vehicles, delivery via drones, and Uber Elevate, which, as the firm refers to it, provides aerial ride-sharing. Uber Technologies is headquartered in San Francisco and operates in over 63 countries with over 110 million users that order rides or foods at least once a month. Approximately 76% of its gross revenue comes from ride-sharing and 22% from food delivery.
Read more on UBER →
